R&D | June 10, 2026
FDA greenlights Lilly’s EBGLYSS for ultra-low-frequency dosing in eczema breakthrough
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
Recognition places pharmaceutical excipients leader among the top 5% of companies globally, highlighting progress in emissions reduction, responsible sourcing, and sustainable supply chain practices
Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Nearly 1.43 crore families in West Bengal to benefit as India’s flagship health assurance scheme achieves full national coverage across all States and Union Territories
As official healthcare partner, ShardaCare deployed dedicated medical teams, emergency services, and on-site healthcare infrastructure
Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
